Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity

癌症和自身免疫中 COVID-19 感染的免疫调节

基本信息

批准号：
10710093
负责人：
Ignacio E. Sanz
金额：
$ 54.51万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-30 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10710093
关键词：
2019-nCoV Acute Address African American Antibody Formation Antibody Response Antitumor Response Autoimmune Autoimmune Diseases Autoimmunity B lymphoid malignancy B-Lymphocytes Biology COVID-19 COVID-19 severity COVID-19 vaccination COVID-19 vaccine Cancer Patient Cells Clinical Data Set Defect Development Disease Ensure Enzyme-Linked Immunosorbent Assay Epigenetic Process Equilibrium Future Generations Genetic Transcription Hematologic Neoplasms Heterogeneity Immune Immune response Immune system Immunity Immunologic Monitoring Immunologics Immunology Impairment Inflammation Inflammatory Innate Immune Response Longevity Malignant - descriptor Malignant Neoplasms Malignant neoplasm of lung Measures Mediating Memory B-Lymphocyte Minority Molecular Monitor Nature Non-Small-Cell Lung Carcinoma Outcome Paresis Pathogenesis Pathogenicity Pathway interactions Patients Plasma Cells Population Population Programs Regulation Research Research Personnel Risk Role SARS-CoV-2 immunity SARS-CoV-2 infection Sampling Scientist Systemic Lupus Erythematosus T cell response T-Lymphocyte Target Populations Technology Time Tumor Antigens University Hospitals Vaccines Viral Virus Virus Diseases Work adaptive immune response antiviral immunity cancer therapy coronavirus disease density experience high risk immune checkpoint blockade immunopathology immunoregulation infection rate inflammatory milieu insight interest long term memory mortality multidisciplinary neutralizing antibody pathogenic autoantibodies patient population post SARS-CoV-2 infection programs prospective recruit repository response serosurveillance success translational study tumor

项目摘要

Abstract: The Emory U54 SeroNET U54 program is a multidisciplinary program that brings together experienced team of investigators to tackle fundamental issues relating to immunity to SARS CoV-2, particular in patients with cancer and autoimmunity. The team has a long track record of prior work in basic and translational studies in the setting of viral infections, vaccines and cancer. The program consists of 3 interacting projects and two essential cores in addition to the administrative core. Studies in project 1 (led by Sanz) will study the biology of SARS CoV-2 specific effector B cell responses in patients with autoimmunity, with a particular focus on extrafollicular B cell pathway. Studies in project 2 (led by Sekaly and Wrammert) will study the role of inflammatory milieu in regulating antiviral immunity and in the development of long term memory responses. Studies in project 3 (led by Dhodapkar and Ahmed) will focus on studying the impact of specific cancer therapies, in particular B/plasma cell depleting therapies in patients with B/plasma cell malignancies, and immune checkpoint blockade in patients with lung cancer. These studies will also set the stage for studying immune responses to future SARS CoV-2 vaccines in patients with autoimmunity as well as cancer patients. The programs are supported by active cores (led by Roback and Neish) which have experience with monitoring immunity to SARS CoV-2. Together, this program will not only provide basic insights into immune-pathogenesis of COVID, but also provide the consortium with access to unique patient populations at higher risk of COVID-related mortality.

抽象的：埃默里大学 U54 SeroNET U54 项目是一个多学科项目，汇集了经验丰富的调查员团队解决与豁免有关的基本问题 SARS CoV-2，特别是癌症和自身免疫患者。团队有很长的病毒感染背景下基础研究和转化研究的先前工作记录，疫苗和癌症。该计划由 3 个相互作用的项目和两个基本项目组成除行政核心外的核心。项目 1 的研究（由 Sanz 领导）将研究 SARS CoV-2 患者特异性效应 B 细胞反应的生物学自身免疫，特别关注滤泡外 B 细胞途径。项目研究 2（由 Sekaly 和 Wrammert 领导）将研究炎症环境在调节中的作用抗病毒免疫和长期记忆反应的发展。研究于项目 3（由 Dhodapkar 和 Ahmed 领导）将重点研究特定的影响癌症治疗，特别是 B/血浆患者的 B/浆细胞耗竭疗法细胞恶性肿瘤和肺癌患者的免疫检查点阻断。这些研究还将为研究未来 SARS CoV-2 的免疫反应奠定基础自身免疫患者和癌症患者的疫苗。这些程序是由具有以下经验的活跃核心（由 Roback 和 Neish 领导）支持监测对 SARS CoV-2 的免疫力。总之，该计划不仅将提供基本的深入了解新冠病毒的免疫发病机制，同时也为联盟提供接触新冠病毒相关死亡风险较高的独特患者群体。